A major side effect of cancer chemotherapy is myelosuppression. Expression of drug-resistance genes in hematopoietic stem cells (HSC) using gene transfer methodologies holds the promise of overcoming marrow toxicity in cancer chemotherapy. Adequate protection of marrow cells in cancer patients from myelotoxicity in this way would permit the use of escalating doses of chemotherapy for eradicating residual disease. A second use of drug-resistance genes is for coexpression with a therapeutic gene in HSCs to provide a selection advantage to gene-modified cells. In this review, we discuss several drug resistance genes, which are well suited for in vivo selection as well as other newer candidate genes with potential for use in this manner.
Introduction
Hematopoietic stem cells (HSCs) are defined by their properties of self-renewal, pluripotency, and life-long persistence following transplantation in the host. HSCs are easily accessible and deliverable back to recipients by well-established transplantation methods. Thus transfer and expression of drug-resistance genes into HSCs would ensure the protection of not only the stem cells but also their differentiated progeny. The attributes of HSCs also make them an attractive target for correction of genetic defects in different hematological lineages. For example, HSCs can be used for gene therapy of hemoglobinopathies (thalassemia, sickle-cell anemia) or immune-deficiency disorders (e.g. severe combined immune deficiency or SCID). Drug resistance genes are being considered in the latter context to provide a mechanism for selection or enrichment of genemodified cells to improve the efficacy of gene therapy. The reader is referred to several recent reviews 1-3 for additional information not covered in detail here.
Gene delivery into HSC
In order to permanently mark or modify HSCs, most investigators use retroviral vectors since they have the ability to integrate into the host cell genome. g-retroviral vectors have been extensively used for this purpose but more recently, lentivirus-based vectors have gathered increasing interest due to their demonstrated superiority to g-retroviral vectors for gene delivery into HSCs. [4] [5] [6] [7] Retroviral vectors have been shown to be effective in correcting genetic disorders in small animal models such as mice. However, success has been meager in large animals including humans. Gene therapy has been particularly successful wherein the therapeutic gene confers a growth advantage to the gene-modified cells. This is exemplified by the remarkable success of gene transfer of common g-chain cytokine receptor to HSCs in children lacking the relevant gene resulting in SCID. [8] [9] [10] The success of gene therapy in SCID patients is attributed to not only improved transduction procedures and optimized in vitro culture conditions for HSCs using newer combinations of cytokines, but also to the growth advantage conferred to gene-modified lymphoid progeny by the particular therapeutic gene used (g-chain of T-cell receptor). Similar success has not been forthcoming for other diseases such as mucopolysaccharidosis or thalassemia, where there is no growth advantage for genemodified cells and the level of marked cells in the peripheral blood of transplanted large animals or humans is rather low to begin with. This can be explained by inefficient gene transfer into HSCs or poor engraftment of transduced long-term repopulating HSCs.
Engraftment can be improved by eliminating the endogenous, nontransduced HSCs by treatment of the recipient with myeloablative or myelosuppressive doses of total body irradiation or chemotherapeutic agents prior to transplantation of the transduced stem cells. This approach has the disadvantage, that it does not affect the nontransduced stem cells in the transplant. The nontransduced HSCs in the transplant, which usually outnumber the transduced HSCs, have the advantage in engraftment. Elimination of nontransduced cells by selection ex vivo prior to transplant, although attractive, has its disadvantages. Selection of gene-modified cells requires further ex vivo manipulation of HSCs following gene transfer by viral vectors, which in itself requires one or more days of culture of HSCs. This would include extra time in culture to obtain a level of transgene expression high enough for sorting by flow cytometry (if the marker gene is either expressed on the surface and available for antibody binding or is a fluorescent protein) or for drug selection and time of exposure to the drug itself. Such increased time in culture has been shown to decrease the number of pluripotent HSCs, thereby compromising long-term engraftment capability. 11, 12 Therefore, selection of gene-modified cells prior to transplant is generally not carried out.
In vivo selection of HSCs, in contrast to ex vivo selection, allows the selective outgrowth of transduced HSCs in their natural environment after transplantation. For in vivo selection, a selection gene alone or together with a potentially therapeutic gene, is introduced into HSCs. The HSCs are transplanted into the recipient and the appropriate selection agent is administered after allowing time for the engraftment of the transplant. Engraftment occurs usually around 4 weeks for both murine or canine models.
The preferential expansion of transduced cells following transplant can be achieved as follows: (a) by modifying the HSCs with genes that provide a proliferative or growth advantage; (b) by modifying HSCs with drug resistance genes that will allow the elimination of nontransduced cells or (c) by using a combination of both. 13, 14 An example of a gene that provides a proliferative advantage is the HoxB4 gene. Expression of this gene increases self-renewal capacity of HSCs and thereby increases the number of transduced HSCs over nontransduced HSCs. [15] [16] [17] Genes that express recombinant growth factor receptors, containing molecular switches, that can be controlled by pharmacological inducers which bind to the switches, can also be used for providing proliferative advantage to HSCs. The pharmacological inducers bring about dimerization of engineered growth factor receptors resulting in selective expansion of gene-modified HSCs. 18 These approaches using growth factor receptors will not be discussed further here.
In vivo selection using drug-resistance genes
The essential requirements for in vivo stem cell selection using drug-resistance genes are as follows: (1) the drug resistance gene should not be expressed, or expressed at a low level, in nontransduced HSCs, but at sufficiently high level in transduced stem cells, (2) the selective cytotoxic drug should be able to deplete the majority of nontransduced stem cells, (3) the selective drug should have little nonhematopoietic toxicity and (4) the selective drug should preferably be not genotoxic for use in nonmalignant conditions.
Several genes have been identified that confer resistance to cytotoxic drugs and can be used for selection of genemodified HSCs in vivo (Figure 1) . These include the genes for multidrug resistance (MDR1), multidrug resistanceassociated protein 1 (MRP1), dihydrofolate reductase (DHFR), aldehyde-dehydrogenase (ALDH), glutathione-S-transferase (GST), cytosine deaminase (CDD) and methylguanine-DNA-methyltransferase (MGMT). Of these, the DHFR, MDR1, MGMT and GST genes (Table 1) have been successfully used for selection of HSCs in vivo in animal models [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and are described in greater detail below.
Dihydrofolate reductase
Dihydrofolate reductase or DHFR, was the first drug resistance gene used for retrovirus vector gene transfer into murine and canine hematopoietic cells. 31, 32 This protein plays an essential role in thymidilate synthesis by regenerating tetrahydrofolate (Figures 1 and 2) . The corresponding selective drugs, methotrexate (MTX) or the related drug, trimetrexate (TMTX), inhibit the wildtype enzyme. Several mutants of DHFR have been identified that are resistant to these drugs. [33] [34] [35] These include the leucine to tyrosine substitution at codon 22 (L22Y) and the phenylalanine to serine substitution at codon 31 (F31S). Double mutations, L22Y and F31S or L22Y and F31R, of DHFR provide much higher resistance to MTX than each single mutant. 36, 37 Expression of mutant DHFR can protect hematopoiesis of transplanted mice from the cytotoxic effects of methotrexate and trimetrexate. 20, 21 The advantage of DHFR over other drug-reistance genes, such as MGMT (discussed below), is that the drugs used for in vivo selection of DHFR (MTX and TMTX) are not genotoxic whereas the drugs used for selection of MGMT, (BCNU and TMZ) are genotoxic. The major drawback of antifolates as selective agents is their inability to kill resting or noncyling cells. However, cycling cells, such as hematopoietic colony forming progenitors, can also avoid being killed by anitfolates. 38 The reason for MTX or TMTX not killing these cells is that they express transport proteins that allow uptake of extracellular nucleosides for nucleotide synthesis by the salvage pathway, thereby, bypassing the need for de novo nucleotide synthesis and thus circumventing antifolate toxicity. 39 This necessitates the use of an inhibitor of the nucleoside transport such as nitrobenzylmercaptopurineriboside phosphate (NBMPR-P), to achieve successful in vivo selection with antifolate drugs 27 . While successful in the murine model, the same approach 27 was not able to achieve stable in vivo selection with the DHFR in a non-human primate model. 40 The explanation given for this lack of efficacy is that large animals have fewer cycling HSCs than mice.
Multi-drug resistance gene
The mutli-drug resistance gene, MDR1, encodes an ATPdependent plasma membrane efflux pump, P-glycoprotein (P-gp) (Figure 1 ). In contrast to the products of other drug resistance genes, the P-gp extrudes a broad range of hydrophobic drugs from cells, including vinca alkaloids, anthracyclines, epipodophyllotoxins, colchicine, actinomycin D, taxol and taxotere. 41 Transfer and expression of human MDR1 in marrow cells has been used to protect hematopoietic cells against myelotoxic drugs. Transgenic mice expressing the human MDR1 gene and normal mice transplanted with marrow from MDR1 expressing transgenic mice, did not develop leukopenia after treatment with cytotoxic drugs 42, 43 presumably due to chemoprotection of transduced cells by MDR1 gene expression. Similarly, retroviral mediated transfer of the human MDR1 gene into mouse marrow cells has been shown to protect transduced cells from chemotherapeutic toxicity in vivo. 22, 23, 44 Mutants of P-gp can be used to tailor drug resistance profiles. For instance, the wild-type version of human MDR1 (containing Gly at position 185) confers preferential resistance against vinblastine while the mutant with Val at position 185 confers resistance to colchicine. 45 Vinblastine is effective against lymphoma cells in the dog and human and its main side effect is marrow toxicity. In this context, the wild-type MDR1 would be used to provide protection against myelosuppression. MDR1 can be combined with other drug resistance genes to broaden the spectrum of drugs for combinatorial chemoprotection of transduced HSCs. [46] [47] [48] [49] MDR1 has been successfully used for in vivo selection of transduced HSCs in murine and canine models. Sugimoto et al. 50 used a bicistronic retroviral vector to coexpress MDR1 and gp91 in murine HSCs. They were able to show efficient selection of transduced cells ex vivo with vincristine and in vivo using paclitaxel. In studies using a canine transplantation model, a bicistronic retroviral vector construct coexpressing MDR1 and human IL-2 receptor common g-chain cDNAs was used for in vivo selection of HSCs with paclitaxel. 51 Two of three dogs involved in this study died from myelosupression resulting from the administration of paclitaxel at dosages of 140 or 175 mg/m 2 . The only surviving animal received paclitaxel three times at a lower dosage of 125 mg/m 2 . In this dog, the transduced genes were found to be expressed in multiple lineages (granulocytes, monocytes and lymphocytes) indicating transduction of pluripotent stem cells. The MDR1 transgene expression was detectable for more than 1 year after discontinuing paclitaxel treatment. There appeared to be no abnormalities of hematopoiesis following selection of transduced cells with paclitaxel.
Despite its potential uses, MDR1 has the following disadvantages. It is expressed at relatively high levels in untransduced HSCs. 52 The MDR1 cDNA is prone to rearrangements because of cryptic RNA splicing sites within the coding sequence. 53 Finally, the observation that expression of MDR1 cDNA in mice is associated with the development of a myeloproliferative disorder resembling chronic myeloid leukemia 54 has diminished enthusiasm for the use of this gene. However, other studies in mice using serial transplantation of MDR1 overexpressing marrow cells, 44 as well as studies of transplantation and in vivo selection of MDR1 transduced marrow cells in cancer patients [55] [56] [57] [58] [59] [60] [61] have not revealed the development of a malignant phenotype. In a recent study Modlich et al. 62 demonstrated that leukemogenesis in mice transplanted with marrow mononuclear cells transduced with MDR1 containing retroviral vector correlated with increased number of vector integration sites in cellular proto-oncogenes and could not be attributed to the MDR1 transgene.
The P-gp also has a lipid translocase function. 63 This function may be exploited as a mechanism for controlling the growth of MDR1 transduced cells. Madin-Darby canine renal cells, transduced with a retroviral vector encoding MDR1, showed an accumulation of the glycosphingolipid receptor for the Escherichia coli-derived verotoxin in cellular membranes. 64 This rendered the cells sensitive to verotoxin by approximately a millionfold over unmodified cells. Thus MDR1 can be used for both positive and negative selection of cells overexpressing P-gp.
Methyl-guanine methyl transferase
Methyl-guanine methyl transferase (MGMT) gene encodes O 6 -alkylguanine-DNA-alkyltransferase (AGT), which is a DNA repair protein. AGT removes alkyl lesions from the O 6 position of guanine and to a much lesser degree from the O 4 position of thymidine (Figures 1  and 3 ). Since the alkyl group remains associated with an active center of the AGT molecule and prevents the recycling of the molecule, MGMT is not a true enzyme in a strict sense. Expression of MGMT provides resistance to monofunctional methylating agents such as dacarbazine and procarbazine as well as bifunctional chloroethylating agents such as the nitrosoureas like 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or carmustine, ACNU or nimustine and temozolomide. 65, 66 AGT expression shows considerable variation in mammalian tissues. For instance, liver cells contain high AGT activity while HSCs possess low activity, explaining the prolonged myelosuppression after nitrosourea treatment. 67 For this reason, gene transfer of MGMT genes into hematopoietic stem cells is of considerable interest for in vivo selection of HSCs. Transplantation of marrow cells, transduced with retroviral vectors containing wild-type human MGMT cDNA, has been shown to increase resistance of hematopoietic cells to BCNU in vivo. 24 Repetitive in vivo BCNU administration increased the proportion of hematopoietic cells in mice containing the wild-type MGMT transgene. 68 To improve the effectiveness of the use of MGMT for in vivo selection, drugs have been identified that inhibit endogenous MGMT/AGT. O 6 -benzylguanine (BG), a pseudosubstrate that inactivates endogenous AGT has been shown to increase the cytotoxic effect of BCNU and other chloroethylating agents. 69 BG forms an S-benzylcysteine moiety at the cysteine acceptor site of the wildtype protein, resulting in irreversible inactivation of AGT. 70 Several mutants of human MGMT have been identified that show increased resistance to BG while retaining the ability to remove alkylator-induced O 6 adducts. 71, 72 These mutants allow the use of BG to inactivate endogenous AGT, thereby increasing the cytotoxic effect of nitrosoureas on nontransduced hematopoietic cells while protecting those hematopoietic cells transduced with retroviral vectors containing the mutant MGMT cDNAs. Human MGMT mutants P140A and G156A have shown a 40-and 240-fold higher resistance to BG compared with wild-type MGMT, 72 while P140K has been shown to be over 1000-fold more resistant to BG. 73 Using a murine stem cell transplant model, Ragg et al. 29 have shown that the P140K mutant is superior to the P140A mutant and wild-type MGMT in protecting bone marrow in vivo from BG/BCNU toxicity. They also demonstrated by serial marrow transplantations that the combined use of BG and BCNU leads to improved in vivo selection of chemoresistant, repopulating HSCs. Persons and coinvestigators convincingly demonstrated, in a murine model of beta-thalassemia, that coexpression of MGMT with the g-globulin gene, followed by in vivo selection using three cycles of BG and BCNU, lead to correction of the disease phenotype. This study showed for the first time that in vivo selection can overcome the low levels of engraftment of genetically marked HSCs Gene therapy with drug resistance genes M Zaboikin et al seen when using nonmyeloablative conditioning regimens for marrow transplant. 30 We recently described the cloning of canine MGMT gene and the creation of a P144K mutant (P144K) that renders the canine MGMT more resistant to BG than the wild-type protein. 74 The canine MGMT was shown to be as efficient as the human MGMT for selection of gene modified cells in vitro. These studies pave the way for testing the canine MGMTs in canine models of genetic disorders or cancer. The canine MGMT has the advantage of decreased likelihood of elimination of gene marked cells by an immune response in the dog. Neff et al. 75 demonstrated successful in vivo selection of human MGMT transduced allogeneic donor canine marrow cells in dogs. In other studies, Neff et al. 76 also demonstrated the use of MGMT for in vivo selection of transduced cells in dogs after autologous transplantation of canine CD34 positive cells transduced with a retroviral vector expressing the P140K mutant of human MGMT. Marking of peripheral blood cells was multilineage with predominant marking of granulocytes. The transplanted animals tolerated escalating doses of temozolomide without signs of thrombocytopenia and other toxicities related to drug treatment. This augurs well for the evaluation of MGMT in clinical trials to overcome marrow toxicity associated with high-dose cancer chemotherapy.
Glutathione S-transferase
Glutathione S-transferase (GST) represents a family of proteins that protect cells from oxidative injury. GST proteins can detoxify metabolites containing carbonyl, peroxide and epoxide groups resulting from oxidative injury. GSTs can also detoxify a wide range of xenobiotics and are therefore useful as drug-resistance markers. GST proteins provide chemoprotection by conjugating the thiol group in the reduced tripeptide glutathione with drugs containing an electrophilic center (Figure 1) . They also bind directly to nonsubstrate ligands and can detoxify oxidative damage that results from drug exposure. GST proteins provide resistance to many drugs including alkylating agents such as melphalan, cis-platin, adriamycin and etoposide. GST proteins are either cytosolic, mitochondrial or membrane bound, and only the cytosolic forms have been used for chemoprotection. 77 Several cytosolic isoforms of GST are known: a, m, p, s and y families. Rat GST alpha5 (also referred to as Yc2) provides the greatest level of resistance to most commonly used drugs. 78 Gene transfer of GST genes into HSCs is of interest to increase resistance to cytotoxic drugs because primitive hematopoietic cells do not express GST, particularly the alpha version. 79 The efficacy of GST in providing drug-resistance was first demonstrated in in vitro experiments in NIH 3T3 fibroblasts, 80 followed by experiments in primary hematopoietic cells. 81, 82 Transfer of GST p into murine marrow cells allowed in vivo selection of hematopoietic stem cells using cyclophosphamide both in the primary recipient of the gene modified transplant as well as in mice after serial transplants of marrow from the primary marrow recipients 28 providing evidence of the utility of GST for myeloprotection. In other studies, several bicistronic vectors were developed to coexpress GST transgene together with a second drug resistance marker with the aim to broaden the scope of chemoprotection. 83, 84 Additional studies with GST are warranted to determine the usefulness of GST for in vivo selection and myeloprotection.
Newer candidates for in vivo selection
Aldehyde dehydrogenase Aldehyde dehydrogenase (ALDH) catalyzes the detoxification of cyclophosphamide, 4-hydroperoxycyclophosphamide (active metabolite of cyclophosphamide), mafosfamide, ifosfamide and 4-hydroperoxyfosfamide. Two classes of ALDH have been described: ALDH1 and ALDH3. Both classes are capable of detoxification of the above mentioned drugs. 85 Detoxification of cyclophosphamide is achieved by conversion of aldophosphamide, a metabolite of cyclophosphamide, to the inactive compound, carboxyphosphamide, thereby preventing the decomposition of aldophosphamide to its cytotoxic derivative, phosphoramide mustard. Human hematopoietic progenitor cells have increased amounts of ALDH. 86 This can be exploited for the isolation of HSCs by flow cytometry, using a fluorescent substrate for ALDH. 87 The overexpression of either ALDH1 88, 89 or ALDH3 90 has been shown to provide increased resistance to 4-hydroperoxycyclophosphamide or mafosfamide in vitro, after retroviral transduction using a number of different cell lines. Bicistronic retroviral vectors encoding ALDH1 and a mutant DHFR can be used to provide dual resistance to 4-hydroperoxycyclophosphamide and MTX in NIH 3T3 fibroblasts, CD34-enriched human peripheral blood progenitor cells, and murine marrow cells. 91 High levels of expression of ALDH in HSCs, and short half-life of the ALDH1 mRNA 92 are potential drawbacks to the use of this drug-resistance gene.
Cytidine deaminase
Nucleoside analogs such as cytosine arabinoside (ara-C) and 2 0 2 0 -difluorodeoxycytidine are important drugs for the treatment of acute myeloid leukemia, but can cause severe myelosuppression. Increased resistance to ara-C was initially observed in human myeloblasts and cell lines overexpressing cytidine deaminase (CDD). 93, 94 CDD deaminates cytosine nucleosides and their analogs such as ara-C and thereby prevents the accumulation of intracellular ara-CTP, the active metabolite of ara-C (Figures 1 and 4) . 95 Overexpression of CDD in mouse fibroblasts, hematopoietic cell lines and primary hematopoietic cells provides resistance to ara-C in vitro.
96-100
Thus CDD shows great promise for myeloprotection in situations that warrant the use of ara-C.
Multidrug-resistance-associated protein
The multidrug-resistance-associated protein (MRP1) is a member of the ATP-binding cassette transporter super-family and a transmembrane efflux transporter similar to P-gp (Figure 1 ). MRPs are organic anion transporters. 101 They transport anionic drugs, such as methotrexate, and neutral drugs conjugated to glutathione, glucuronate or sulfate. Of the 10 known members of the MRP family, only MRP1 has received the most scrutiny and may be useful clinically. 41 The cDNA of MRP1 was cloned from a small-cell lung carcinoma cell line (H69/AR) that was resistant to multiple drugs, but did not overexpress P-gp. 102 The MRP1 gene was subsequently found to be overexpressed in several other P-gp negative cancer cell lines [103] [104] [105] that were also resistant to multiple drugs. MRP1 overexpressing cells show increased resistance to podophyllins, certain anthracyclines and vinca alkaloids but, unlike P-gp-overexpressing cells, have little or no increased resistance to colchicine, mitoxantrone or taxol. [103] [104] [105] [106] [107] Transfection of MRP1 cDNA in human cells is sufficient to confer multidrug resistance similar to that of the MRP-overexpressing cancer cell lines. 107, 108 NIH 3T3 fibroblasts, transduced with MRP1 expressing retroviral vectors, have increased resistance against doxorubicin, etoposide and vincristine. 109 Overexpression of MRP1 in long-term repopulating HSCs in mice, provides protection against doxorubicin induced leukopenia. 110 Since MRP1 prefers glutathione conjugated substrates, 111 coexpression of MRP1 with GST might provide enhanced protection in transduced cells. This hypothesis is supported by the studies of Rappa et al. 112 who used Friend mink cell focus-forming/murine embryonic stem cell virus based vector to coexpress MRP1 and g-glutamylcysteine synthetase (g-GCS), another enzyme involved in glutathione biosynthesis, in 3T3 fibroblasts and murine hematopoietic cells. The transduced cells, including primary murine myeloid progenitor cells, coexpressing both MRP1 and g-GCS transgenes, became more resistant to the alkylating agents, VP-16 and melphalan, than cells expressing only MRP1.
Clinical trials of drug resistance genes
Very few of the above mentioned drug resistance genes have been tested in clinical trials. Patients with breast cancer, ovarian cancer, lymphoma or germ cell tumors have received autologous CD34 þ hematopoietic cells marked with MDR1. In all these trials, CD34 þ cells derived from the bone marrow or peripheral blood were marked with retroviral vectors encoding MDR1. [55] [56] [57] [58] [59] [60] [61] In one trial, 59 an expansion of MDR1 transduced hematopoietic cells, relative to control neo transduced cells, was observed in some patients after chemotherapy with drugs that could be extruded by P-gp. In another study of patients with germ cell tumors, Abonour et al., 61 using an improved gene transfer protocol that used CH-296 fragment of fibronectin during ex vivo transfer of MDR1 gene into HSCs, observed persistence of the transgene for more than a year after autologous transplantation in four out of nine patients. However, the utility of MDR1 for myeloprotection was not evaluated. MGMT(G156A) is being evaluated for myeloprotective effect against BG and BCNU in patients with advanced solid tumors and non-Hodgkin's lymphoma. 113 The utility and safety of MGMT, MDR1 and other potential transgenes for correction of genetic defects or myeloprotection in cancer chemotherapy requires further pre-clinical and clinical studies.
Conclusions and future directions
The variety of selective markers with different drug resistance profiles that are now available, make it possible for gene therapy to be used to overcome myelotoxicity in cancer chemotherapy. As with any form of new treatment, the use of drug resistance genes for myeloprotection in cancer chemotherapy has to undergo rigorous testing in large animal models and in clinical trials, to establish the efficacy and long-term safety of this approach. Future clinical trials also need to consider the mutagenic risk of retroviral gene transfer that has been recently highlighted in mice and humans. [114] [115] [116] In addition, obstacles to gene therapy in large animal models and in humans, such as poor efficiency of gene transfer and lack of sustained transgene expression, need to be addressed to make this form of treatment a reality for cancer patients. Mechanism of action of cytidine deaminase. Cytosine arabinoside (ara-C) inhibits nuclear DNA synthesis by interfering with DNA polymerase function. Cytidine deaminase deaminates ara-C to a much less active compound, arabinosyluracil (ara-U) that is then excreted.
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